Ursodeoxycholic Acid
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Ursodeoxycholic Acid: Homozygous familial hypercholesterolemia
One-Sentence Summary
Ursodeoxycholic acid (UDCA) was originally used to treat gallstone diseases (cholelithiasis, cholecystolithiasis, choledocholithiasis) and primary biliary cholangitis. The TxGNN model predicts it may be effective for homozygous familial hypercholesterolemia, but there are currently 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Homozygous familial hypercholesterolemia |
| TxGNN Prediction Score | 0.9986 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 8 of 8) |
| Number of DINs | 8 (marketed: 8) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, UDCA is a bile acid that modulates the bile acid pool and hepatic cholesterol handling. Its efficacy in gallstone disease and primary biliary cholangitis is established, and mechanistically it might reduce intestinal cholesterol absorption and hepatic cholesterol synthesis.
However, this link is plausible but unverified. Homozygous familial hypercholesterolemia is caused by defects in the LDL receptor pathway (LDLR, APOB, PCSK9 or LDLRAP1 variants). Bile acid modulation is unlikely to compensate for absent LDL receptor function, so any effect would probably be minor compared with established therapies such as statins, ezetimibe, PCSK9 inhibitors, lomitapide, evinacumab and LDL apheresis.
The high TxGNN model (deep learning) score may reflect similarities the model learned between related diseases, not biological evidence, and should be treated as a hypothesis-generating signal, not as support for clinical use.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02273500 | PMS-URSODIOL C | Not specified | Not specified |
| 02544024 | NRA-URSODIOL | Not specified | Not specified |
| 02426919 | GLN-URSODIOL | Not specified | Not specified |
| 02472392 | JAMP-URSODIOL | Not specified | Not specified |
| 02544032 | NRA-URSODIOL | Not specified | Not specified |
Showing 5 of 8 valid single-ingredient licences. None of the licences is cancelled.
Safety Considerations
- Drug Interactions: The interaction screen returned 100 records; the first 20 reviewed are listed below. Most are of unknown severity.
- Minor: cyclosporine, aluminum hydroxide, magaldrate
- Severity unknown: cyanocobalamin, calcitriol, folic acid, pravastatin, ramipril, lorazepam, tramadol, fluconazole, oseltamivir, erythromycin, sildenafil, pantoprazole, citalopram, moxifloxacin, nelfinavir, glimepiride, indinavir
Note that aluminum-containing antacids are commonly reported to reduce bile acid absorption, and cyclosporine levels may be affected. The clinical significance should be confirmed against the package insert.
Warnings and contraindications from the Canadian package insert are not available. Please refer to the package insert for these.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score (L5), with no clinical trials or literature. The proposed mechanism is weak for a disease caused by LDL receptor-pathway defects, and effective approved alternatives already exist.
To proceed, the following is needed:
- Mechanism of action data for UDCA, to assess the biological link to LDL receptor-deficient disease
- A systematic literature and trial search on UDCA and lipid lowering in familial hypercholesterolemia
- Canadian package insert warnings, contraindications and approved indication text for the 8 DINs
- Preclinical or early-phase data showing a meaningful LDL-C effect in homozygous patients, compared with current standard therapy
- Review of the full interaction list, particularly with lipid-lowering agents such as pravastatin
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.